|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | NXY-059治疗急性缺血性卒中显示文摘Background: NXY-059 is a free-radical-trapping agent that is neuroprotective in animal models of stroke. We tested whether it would reduce disability in humans after acute ischemic stroke. Methods: We conducted a randomized, double-blind, placebo-controlled trial involving 1722 patients with acute ischemic stroke who were randomly assigned to receive a 72-hour infusion of placebo or intravenous NXY-059 within 6 hours after the onset of the stroke. The primary outcome was disability at 90 days, as measured according to scores on the modified Rankin scale for disability (range, 0 to 5, with 0 indicating no residual symptoms and 5 indicating bedbound, requiring constant care). Results: Among the 1699 subjects included in the efficacy analysis, NXY-059 significantly improved the overall distribution of scores on the modified Rankin scale, as compared with placebo (P = 0.038 by the Cochran-Mantel-Haenszel test). The common odds ratio for improvement across all categories of the scale was 1.20 (95 percent confidence interval, 1.01 to 1.42). Mortality and rates of serious and nonserious adverse events were each similar in the two groups. NXY-059 did not improve neurologic functioning as measured according to the National Institutes of Health Stroke Scale (NIHSS): the difference between the two groups in the change from baseline scores was 0.1 point (95 percent confidence interval, -1.4 to 1.1; P = 0.86). Likewise, no improvement was observed according to the Barthel index (P = 0.14). In a post hoc analysis of patients who also received alteplase, NXY-059 was associated with a lower incidence of any hemorrhagic transformation (P = 0.001)and symptomatic intracranial hemorrhage (P = 0.036). Conclusions: The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. Additional research is needed to confirm whether NXY-059 is beneficial in ischemic stroke. | Lees K. R. Zivin J. A. Ashwood T. et 郭俊(译) | 2006 | 世界核心医学期刊文摘(神经病学分册)2006，2，6： | 12 |
| 2 | Transarticular shear fractures of the distal humerus显示文摘 | Neil Ashwood Manish Verma Mark Hamlet Anand Garlapati Quentin Fogg | 2010 | Journal of Shoulder and Elbow Surgery2010，，1： | 3 |
| 3 | NXY-059 for acute ischemic stroke显示文摘 | Zivin JA Ashwood T | 2006 | N Engl J Med2006，354，： | 1 |
| 4 | Funtional interactions between mucosal IL - 1, IL - 1 ra and TGF - betal in ulcerative cohtis 显示文摘 | Ashwood P Harvey R Verjee T | 2004 | In- flamm Res2004，53，2： | 1 |
| 5 | Screening fordown syndrome in the United States: results of surveys in 2011and 2012显示文摘 | Palomaki GE Knight GJ Ashwood ER | 2013 | Arch Pathol Lab Med2013，137，： | 1 |
| 6 | Free radical trapping as a therapeutic approach to neuroproteetion in stroke: experimental and clinical studies with NXY-059 and free radical scavengers 显示文摘 | GREEN AR ASHWOOD T | 2005 | Curr Drug Targets CNS Neurol Disord2005，4，2： | 1 |
| 7 | Functional interactions between mucosal IL-l,IL-lra and TGF-beta 1 in ulcer ative colitis显示文摘 | Ashwood P Harvey R Verjee T | 2004 | Inflamm Res2004，53，2： | 1 |
| 8 | Reduced levels of immuno- globulin in children with autism correlates with behavioral symp- toms 显示文摘 | Heuer L Ashwood P Schauer J | 2008 | Autism Res2008，1，： | 1 |
| 9 | Preliminary evidence of the in vitro effects of BDE-47 on innate immune responses in children with autism spectrum disorders 显示文摘 | Ashwood P Schauer J Pessah IN | 2009 | J Neuroimmunol2009，208，： | 1 |
| 10 | Screening for Down Syndrome in the United States: Results of Surveys in 2011 and 2012显示文摘 | Palomaki Glenn E Knight George J Ashwood Edward R Best Robert G Haddow James E | 2013 | Archives of Pathology & Laboratory Medicine2013，，7： | 1 |
| 11 | Neurophysiological responses to faces and gaze direction differentiate children with ASD,ADHD and ASD+ADHD显示文摘 | Tye C Mercure E Ashwood KL | 2013 | Dev Cogn Neurosci2013，5，： | 1 |
| 12 | Immune activation of peripheral blood and mucosal CD3+ lymphoeyte cytokine profiles in children with autism and gastrointestinal symptoms显示文摘 | Ashwood P Wakefield A J | 2006 | Joumal of Neuroimmunology2006，173，： | 1 |
| 13 | NXY-059 for acute is- chemic stroke显示文摘 | LEES K ZIVIN J ASHWOOD T | 2006 | N Engl J Med2006，354，6： | 1 |
| 14 | Transarticular shear fractures of the distal humerus 显示文摘 | Ashwood N Verma M Hamlet M | 2010 | J Shoulder Elbow Surg2010，19，1： | 1 |
| 15 | Functional interactions between mucosal IL-1, IL-lra and TGF-beta 1 in ulcerative colitis 显示文摘 | Ashwood P Harvey R Verjee T | 2004 | Inflamm Res2004，53，2： | 1 |
| 16 | Transarticular shear fractures of the distal humerus显示文摘 | Ashwood N Verma M Hamlet M | 2010 | J Shoulder Elbow Surg2010，19，： | 1 |
| 17 | State of the art intrueness and interlaboratory harmonization for 10 analytes ingeneral clinical chemistry 显示文摘 | Miller WG Myers GL Ashwood ER | 2008 | Arch Pathol Lab Med2008，132，： | 1 |
| 18 | The design and development of a large su- personic tee-jet test cell显示文摘 | Ashwood P F | 1970 | The Aeronautical Journal of the Royal Aeronautical Society1970，74，3： | 1 |
| 19 | Lamellar body counts: a consensus on protocol 显示文摘 | Neerhof MG Dohnal JC Ashwood ER | 2001 | Obstet Gynecol2001，97，2： | 1 |
| 20 | Animal models of stroke:Do they have value for discovering neuroprotective agents? 显示文摘 | Green AR Odergren T Ashwood T | 2003 | Trends Pharmacol Sci2003，24，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员